Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE BESYLATE AND VALSARTAN versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE BESYLATE AND VALSARTAN versus TEVETEN HCT.
AMLODIPINE BESYLATE AND VALSARTAN vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced peripheral vascular resistance. Valsartan is an angiotensin II receptor blocker that selectively blocks the binding of angiotensin II to AT1 receptors, resulting in vasodilation and reduced aldosterone secretion.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Adults: initial combination therapy 5/160 mg (amlodipine/valsartan) orally once daily; titrate based on response, maximum 10/320 mg once daily.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Amlodipine: 30-50 hours (terminal); Valsartan: 6-9 hours. Amlodipine's long half-life allows once-daily dosing; steady state achieved after 7-10 days.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Amlodipine: ~60% renal (10% as unchanged drug), ~20-25% biliary/fecal. Valsartan: ~83% fecal via biliary, ~13% renal (mainly unchanged).
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination